Headlines:

A gene therapy for a retinal dystrophy disorder will cost $850,000

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye. Spark Therapeutics Inc., the Philadelphia-based maker, will make the one-time treatment available to patients with a rare genetic defect that often leads to blindness

  • Written by Robert Woodward
  • Category: Medicine

A warning signal for women using tampons, based on a real tragic experience

Lauren Wasser, a young model, actress and activist, 28, lost her right leg in 2012 due to a near fatal bout of Toxic Shock Syndrome (TSS)  caused by a tampon. At age 24 she contracted gangrene and was placed in a medically-induced coma, before doctors told her she would need to choose between losing her leg or losing her life.

  • Written by James Prewitt
  • Category: Medicine

FDA approved a gene therapy for an inherited form of blindness

The Food and Drug Administration approved Luxturna (voretigene neparvovec-rzyl), a gene therapy developed by Spark Therapeutics, to treat an inherited form of blindness. a genetically modified virus that ferries a healthy gene into the eyes of patients born with retinal dystrophy, a rare condition that destroys cells in the retina needed for healthy vision.

  • Written by James Prewitt
  • Category: Medicine

Comments